Bristol Myers Squibb Company $BMY Stock Bought by PBU The Pension Fund of Early Childhood & Youth Educators

PBU The Pension Fund of Early Childhood & Youth Educators increased its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 6.4% during the third quarter, HoldingsChannel.com reports. The fund owned 233,660 shares of the biopharmaceutical company’s stock after acquiring an additional 13,968 shares during the period. PBU The Pension Fund of Early Childhood & Youth Educators’ holdings in Bristol Myers Squibb were worth $14,580,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of BMY. Pinion Investment Advisors LLC grew its position in shares of Bristol Myers Squibb by 3.8% during the 3rd quarter. Pinion Investment Advisors LLC now owns 4,316 shares of the biopharmaceutical company’s stock valued at $269,000 after purchasing an additional 158 shares in the last quarter. Altura Wealth Advisors Inc. raised its position in shares of Bristol Myers Squibb by 1.2% in the third quarter. Altura Wealth Advisors Inc. now owns 13,717 shares of the biopharmaceutical company’s stock worth $856,000 after buying an additional 161 shares in the last quarter. Capital City Trust Co. FL boosted its stake in Bristol Myers Squibb by 0.7% during the third quarter. Capital City Trust Co. FL now owns 23,321 shares of the biopharmaceutical company’s stock valued at $1,455,000 after buying an additional 167 shares during the period. Eagle Bay Advisors LLC boosted its stake in Bristol Myers Squibb by 2.6% during the third quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company’s stock valued at $408,000 after buying an additional 168 shares during the period. Finally, Blue Bell Private Wealth Management LLC grew its position in Bristol Myers Squibb by 21.1% during the third quarter. Blue Bell Private Wealth Management LLC now owns 969 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 169 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Down 0.8%

BMY opened at $62.42 on Friday. The stock has a market cap of $127.58 billion, a PE ratio of 13.84, a P/E/G ratio of 0.32 and a beta of 0.20. The company has a quick ratio of 1.44, a current ratio of 1.59 and a debt-to-equity ratio of 1.79. Bristol Myers Squibb Company has a 52 week low of $45.26 and a 52 week high of $68.64. The business’s fifty day simple moving average is $61.99 and its 200 day simple moving average is $60.27.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The firm had revenue of $13.07 billion during the quarter, compared to analyst estimates of $12.72 billion. During the same quarter in the previous year, the company posted $1.63 earnings per share. The company’s revenue was up 6.9% compared to the same quarter last year. As a group, research analysts expect that Bristol Myers Squibb Company will post 6.46 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.88%.

Insider Buying and Selling

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Julia A. Haller sold 3,800 shares of Bristol Myers Squibb stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the transaction, the director directly owned 30,279 shares in the company, valued at $1,916,963.49. This trade represents a 11.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.05% of the company’s stock.

Top Bristol Myers Squibb Stories

These are some of the BMY stories that stood out recently:

• Positive Sentiment: Some analysts and commentators consider BMY attractively valued, citing roughly 10 times forward earnings and a view that shares remain below fair value despite a strong multi-year run. That could support investor interest if the company delivers on its cash-flow and pipeline prospects. Our Bristol Myers Squibb Stock Pick Is Up 35%. It’s Still a Good Bet in Healthcare. Bristol Myers Squibb Stock Looks Below Fair Value Following A 41% Run
• Neutral Sentiment: Bristol Myers plans to bring its scientific and clinical teams together in a unified R&D organization, aiming to accelerate development and make better use of new technologies. Research chief Robert Plenge is leaving as part of the change. The strategy could improve productivity, but the leadership transition and results of the restructuring remain uncertain. Bristol Myers to merge scientific, clinical teams under new R&D structure Bristol Myers research chief to depart in evolution of company’s structure
• Negative Sentiment: Drug-price negotiations are a potential longer-term headwind for BMY, with the article describing the company as facing a bigger test in the years ahead. The risk is not presented as an immediate revenue hit, but could weigh on future pricing and growth expectations. Drug pricing risks for pharmaceutical companies

Analysts Set New Price Targets

A number of equities analysts have weighed in on BMY shares. Royal Bank Of Canada restated a “sector perform” rating on shares of Bristol Myers Squibb in a research note on Monday, October 19th. JPMorgan Chase & Co. lifted their price target on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Piper Sandler decreased their price objective on shares of Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating on the stock in a research report on Monday, October 26th. Bank of America reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research note on Friday, October 30th. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 13th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $65.46.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.